The FDA approved the drug in 1997 for preventing osteoporosis in postmenopausal women, and studies have shown that raloxifene appears to protect some women from developing breast cancer.

• fda在1997年批准了该药，开始时用于为绝经期妇女预防骨质疏松。 研究表明，raloxifene似乎可以保护某些妇女不得乳腺癌。